BC-819: Phase I/IIa data

A U.S. and Israeli Phase I/IIa trial in 9 patients showed that twice-weekly 4 and 8 mg BC-819 for 2 weeks met the primary safety endpoint with no drug-related side effects or complaints about pain or ...